Skip to main content
SpringerLink
Log in

Docetaxel - an agent worth pursuing in NSCLC

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

Docetaxel [Taxotere®; Rhône-Poulenc Rorer; phase II] demonstrated the highest antitumour response rate ever reported for any single agent tested against nonsmall cell lung cancer (NSCLC) in trials at the Memorial Sloan-Kettering Cancer Center, New York, US. These promising results were presented at a symposium sponsored by Rhône-Poulenc Rorer which was held during the European Congress of Clinical Oncology (ECCO) in Jerusalem, Israel, in November.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. David Oldfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oldfield, D. Docetaxel - an agent worth pursuing in NSCLC. Inpharma Wkly. 916, 9 (1993). https://doi.org/10.2165/00128413-199309160-00021

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199309160-00021

Search

Navigation